BioGlyco supplement products (including BioGlyco Flow, BioGlyco Capsules, and BioGlyco Blood) are not affiliated with CD BioGlyco.
CD BioGlyco does not manufacture, distribute, or provide after-sales support for these consumer products. For any product-related questions, please contact the original seller directly.
This highly advanced multi-functional targeted formulation features ligand-functionalized liposomes co-loaded with irinotecan and a bromodomain inhibitor. The complex structural framework encapsulates the hydrophilic camptothecin derivative irinotecan within its central aqueous core via an active remote-loading gradient, while simultaneously incorporating the hydrophobic thienotriazolodiazepine compound JQ1 within the lipophilic tail regions of its bilayer shell, whose exterior boundary presents a dense target-mimetic affinity ligand array. This intricate configuration coordinates dual-targeted ligand tracking handles with a protective dual-phase multi-cargo boundary, completely preventing drug crystallization, premature chemical hydrolysis, and physical vesicle aggregation under ambient laboratory testing conditions.
Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.
As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.
*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.
CD BioGlyco is a leading biotechnology company specializing in glycobiology. We deliver high-quality products and services to support cutting-edge research worldwide.